JP2012506237A - Ｄｃ−ｓｉｇｎに対する結合特異性をもつリガンド - Google Patents

Ｄｃ−ｓｉｇｎに対する結合特異性をもつリガンド Download PDF

Info

Publication number
JP2012506237A
JP2012506237A JP2011531514A JP2011531514A JP2012506237A JP 2012506237 A JP2012506237 A JP 2012506237A JP 2011531514 A JP2011531514 A JP 2011531514A JP 2011531514 A JP2011531514 A JP 2011531514A JP 2012506237 A JP2012506237 A JP 2012506237A
Authority
JP
Japan
Prior art keywords
lip1
seq
sequence
sign
variable domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011531514A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012506237A5 (enExample
Inventor
ウィルト，ルドルフ，マリア デ
Original Assignee
ドマンティス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ドマンティス リミテッド filed Critical ドマンティス リミテッド
Publication of JP2012506237A publication Critical patent/JP2012506237A/ja
Publication of JP2012506237A5 publication Critical patent/JP2012506237A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
JP2011531514A 2008-10-21 2009-10-19 Ｄｃ−ｓｉｇｎに対する結合特異性をもつリガンド Pending JP2012506237A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10708508P 2008-10-21 2008-10-21
US61/107,085 2008-10-21
PCT/EP2009/063655 WO2010046337A2 (en) 2008-10-21 2009-10-19 Ligands that have binding specificity for dc-sign

Publications (2)

Publication Number Publication Date
JP2012506237A true JP2012506237A (ja) 2012-03-15
JP2012506237A5 JP2012506237A5 (enExample) 2012-11-22

Family

ID=42062429

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011531514A Pending JP2012506237A (ja) 2008-10-21 2009-10-19 Ｄｃ−ｓｉｇｎに対する結合特異性をもつリガンド

Country Status (16)

Country Link
US (1) US20110257373A1 (enExample)
EP (1) EP2356149A2 (enExample)
JP (1) JP2012506237A (enExample)
KR (1) KR20110071139A (enExample)
CN (1) CN102257009A (enExample)
AR (1) AR073905A1 (enExample)
AU (1) AU2009306424A1 (enExample)
BR (1) BRPI0919714A2 (enExample)
CA (1) CA2740856A1 (enExample)
EA (1) EA201100488A1 (enExample)
IL (1) IL212086A0 (enExample)
MX (1) MX2011004244A (enExample)
TW (1) TW201019962A (enExample)
UY (1) UY32189A (enExample)
WO (1) WO2010046337A2 (enExample)
ZA (1) ZA201102763B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012506371A (ja) * 2008-10-21 2012-03-15 ドマンティス リミテッド 樹状細胞を標的とするための組成物

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013095973A1 (en) * 2011-12-19 2013-06-27 The Rockefeller University Hdc-sign binding peptides
US20250319024A1 (en) * 2021-08-27 2025-10-16 University Of Georgia Research Foundation, Inc. Targeted nanoparticles and their uses related to infectious disease
CN118184795B (zh) * 2022-12-13 2025-03-21 成都维瑾柏鳌生物医药科技有限公司 抗hiv-1的重组蛋白及其应用

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004041865A2 (en) * 2002-11-08 2004-05-21 Ablynx N.V. Stabilized single domain antibodies
WO2004062551A2 (en) * 2003-01-10 2004-07-29 Ablynx N.V. RECOMBINANT VHH SINGLE DOMAIN ANTIBODY FROM CAMELIDAE AGAINST VON WILLEBRAND FACTOR (vWF) OR AGAINST COLLAGEN
JP2007502780A (ja) * 2003-08-21 2007-02-15 リポテック・プロプライエタリー・リミテッド ｉｎｖｉｖｏにおける樹状細胞の標的化
WO2007066109A1 (en) * 2005-12-06 2007-06-14 Domantis Limited Bispecific ligands with binding specificity to cell surface targets and methods of use therefor
WO2007066106A1 (en) * 2005-12-06 2007-06-14 Domantis Limited Ligands that have binding specificity for egfr and/or vegf and methods of use therefor
WO2007085815A2 (en) * 2006-01-24 2007-08-02 Domantis Limited Ligands that bind il-4 and/or il-13
JP2008500830A (ja) * 2004-06-01 2008-01-17 ドマンティス リミテッド 増加した血清半減期を有する二重特異性融合抗体
WO2008070363A2 (en) * 2006-10-31 2008-06-12 Domantis Limited Intrabodies
JP2008521870A (ja) * 2004-12-02 2008-06-26 ドマンティス リミテッド 抗ｉｌ−１ｒ１単一ドメイン抗体および治療使用
JP2008521869A (ja) * 2004-12-02 2008-06-26 ドマンティス リミテッド 血清アルブミンおよびｇｌｐ−１またはｐｙｙを標的とする二重特異性抗体
JP2008533115A (ja) * 2005-03-18 2008-08-21 ドマンティス リミテッド カンジダ抗原に対する抗体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0598108A1 (en) * 1992-06-05 1994-05-25 Dade Produktions AG Rabbit single domain antibody and use thereof
JP4889493B2 (ja) * 2003-05-14 2012-03-07 ドマンティス リミテッド ポリペプチドレパートリーから可逆的にアンフォールドするポリペプチドを回収するための方法
ES2315664T3 (es) * 2003-06-30 2009-04-01 Domantis Limited Anticuerpos de dominio unico (dab) pegilados.
WO2008039432A1 (en) * 2006-09-26 2008-04-03 Alexion Pharmaceuticals, Inc. Compositions and methods for enhancing an adjuvant
CN101182539A (zh) * 2007-11-06 2008-05-21 浙江大学 Dc-sign启动子荧光素酶报告质粒的构建方法

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004041865A2 (en) * 2002-11-08 2004-05-21 Ablynx N.V. Stabilized single domain antibodies
WO2004041862A2 (en) * 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
WO2004062551A2 (en) * 2003-01-10 2004-07-29 Ablynx N.V. RECOMBINANT VHH SINGLE DOMAIN ANTIBODY FROM CAMELIDAE AGAINST VON WILLEBRAND FACTOR (vWF) OR AGAINST COLLAGEN
JP2007502780A (ja) * 2003-08-21 2007-02-15 リポテック・プロプライエタリー・リミテッド ｉｎｖｉｖｏにおける樹状細胞の標的化
JP2008500830A (ja) * 2004-06-01 2008-01-17 ドマンティス リミテッド 増加した血清半減期を有する二重特異性融合抗体
JP2008521870A (ja) * 2004-12-02 2008-06-26 ドマンティス リミテッド 抗ｉｌ−１ｒ１単一ドメイン抗体および治療使用
JP2008521869A (ja) * 2004-12-02 2008-06-26 ドマンティス リミテッド 血清アルブミンおよびｇｌｐ−１またはｐｙｙを標的とする二重特異性抗体
JP2008533115A (ja) * 2005-03-18 2008-08-21 ドマンティス リミテッド カンジダ抗原に対する抗体
WO2007066109A1 (en) * 2005-12-06 2007-06-14 Domantis Limited Bispecific ligands with binding specificity to cell surface targets and methods of use therefor
WO2007066106A1 (en) * 2005-12-06 2007-06-14 Domantis Limited Ligands that have binding specificity for egfr and/or vegf and methods of use therefor
WO2007085815A2 (en) * 2006-01-24 2007-08-02 Domantis Limited Ligands that bind il-4 and/or il-13
WO2008070363A2 (en) * 2006-10-31 2008-06-12 Domantis Limited Intrabodies

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012506371A (ja) * 2008-10-21 2012-03-15 ドマンティス リミテッド 樹状細胞を標的とするための組成物

Also Published As

Publication number Publication date
EA201100488A1 (ru) 2011-12-30
MX2011004244A (es) 2011-05-25
CN102257009A (zh) 2011-11-23
BRPI0919714A2 (pt) 2015-12-08
KR20110071139A (ko) 2011-06-28
IL212086A0 (en) 2011-06-30
US20110257373A1 (en) 2011-10-20
CA2740856A1 (en) 2010-04-29
WO2010046337A2 (en) 2010-04-29
ZA201102763B (en) 2012-09-26
UY32189A (es) 2010-05-31
WO2010046337A3 (en) 2010-07-01
AR073905A1 (es) 2010-12-09
EP2356149A2 (en) 2011-08-17
TW201019962A (en) 2010-06-01
AU2009306424A1 (en) 2010-04-29

Similar Documents

Publication Publication Date Title
US12428497B2 (en) Multispecific antibody constructs
JP7019198B2 (ja) 補体関連疾患の予防及び治療のためのｃ５抗体及び方法
CN105026428B (zh) PD‑l抗体、其抗原结合片段及其医药用途
CN107750255B (zh) 用于cdh3和cd3的双特异性抗体构建体
US20170198062A1 (en) Multi-specific antibody constructs
CN105121467A (zh) 抗cd47抗体及其使用方法
KR20190137077A (ko) T 세포 관여 항체 구축물을 포함하는 저 pH 약제학적 조성물
WO2015057942A1 (en) Human monoclonal antibodies against the middle east respiratory syndrome coronavirus (mers-cov) and engineered bispecific fusions with inhibitory peptides
WO2020108611A1 (zh) 抗cd40抗体、其抗原结合片段及其医药用途
CN114835802B (zh) 针对呼吸道合胞病毒的蛋白结合分子
WO2019076277A1 (zh) 抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途
CN113039208B (zh) 一种抗pd-l1抗原结合蛋白及其应用
JP2012506237A (ja) Ｄｃ−ｓｉｇｎに対する結合特異性をもつリガンド
JP2022528230A (ja) Ｉｌ－５に対する抗体を含有する医薬組成物及びその使用
CN110114370A (zh) 能够与人白细胞介素-6受体结合的抗体或其抗原结合片段
CN106062193A (zh) 新型与人tlr2及人tlr4结合的双特异性抗体
US20230331862A1 (en) Antibody specifically bound to glycosylated ceacam5
JP2020531041A (ja) ポリペプチドとポリペプチドに結合される抗体
WO2023066401A1 (zh) 一种特异性结合人ctla4的抗体及包含其的药物和试剂盒
WO2022002006A1 (zh) Fab-HCAb结构的结合蛋白
TW202544031A (zh) 抗tigit/抗pd-l1雙特異性抗體及其用途
HK40103027A (zh) 抗a-syn/igf1r的双特异性抗体及其用途
HK40127090A (zh) 表皮生长因子受体变体iii抗体
HK40089569A (zh) 新型癌症免疫治疗抗体组合物
WO2021190500A1 (zh) SARS-CoV-2和SARS-CoV交叉中和抗体的制备及应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121003

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121003

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140325

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140819